China Universal Asset Management Co. Ltd. Has $330,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

China Universal Asset Management Co. Ltd. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,920 shares of the biotechnology company’s stock after purchasing an additional 4,129 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $330,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $48,000. KBC Group NV increased its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 4,537 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the period. Exome Asset Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $1,493,000. Finally, Franklin Resources Inc. grew its position in shares of BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 168,790 shares during the period. 85.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday. Finally, Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.90 on Monday. The stock has a 50 day moving average price of $7.63 and a 200 day moving average price of $7.69. The stock has a market capitalization of $1.64 billion, a PE ratio of -12.95 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the business posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.